Emricasan
Emricasan (PF 03491390) is an orally active and irreversible pan-caspase inhibitor. Emricasan inhibits Zika virus (ZIKV) -induced increases in caspase-3 activity and protected human cortical neural progenitors[1].
Product Specifications
CAS Number
254750-02-2
Product Name Alternative
PF 03491390; IDN-6556
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Caspase; Flavivirus
Type
Reference compound
Related Pathways
Anti-infection; Apoptosis
Applications
Cancer-programmed cell death
Field of Research
Cancer; Infection; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/Emricasan.html
Concentration
10mM
Purity
99.81
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
FC1=C(C(F)=C(C=C1F)F)OCC([C@@H](NC([C@@H](NC(C(NC2=C(C=CC=C2)C(C)(C)C)=O)=O)C)=O)CC(O)=O)=O
Molecular Formula
C26H27F4N3O7
Molecular Weight
569.50
Precautions
H302, H315, H319, H335
References & Citations
[1]Barreyro FJ, et al. The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis. Liver Int. 2015 Mar;35 (3) :953-66.|[2]Hoglen NC, et al. Characterization of IDN-6556 (3-[2- (2-tert-butyl-phenylaminooxalyl) -amino]-propionylamino]-4-oxo-5- (2,3,5,6-te trafluoro-phenoxy) -pentanoic acid) : a liver-targeted caspase inhibitor. J Pharmacol Exp Ther. 2004 May;309 (2) :634-40.|[3]McCall M, et al. The caspase inhibitor IDN-6556 (PF3491390) improves marginal mass engraftment after islet transplantation in mice. Surgery. 2011 Jul;150 (1) :48-55.|[4]Tian J, et al. Combination of Emricasan with AP24534 Synergistically Reduces Ischemia/Reperfusion Injury in Rat Brain Through Simultaneous Prevention of Apoptosis and Necroptosis. Transl Stroke Res. 2017 Nov 4.|[5]Gracia-Sancho J, et al. Emricasan Ameliorates Portal Hypertension and Liver Fibrosis in Cirrhotic Rats Through a Hepatocyte-Mediated Paracrine Mechanism. Hepatol Commun. 2019 Apr 22;3 (7) :987-1000.|[6]Xu M, et al. Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen. Nat Med. 2016 Oct;22 (10) :1101-1107.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
Caspase
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
LC419927 20 µg
Flt3 ligand (FLT3LG) (NM_001459) Human Over-expression Lysate
Sign In for Pricing
View Details 
PKSQ050017-01 10 µg
Recombinant Cynomolgus B7-2/CD86 Protein (Fc Tag)
Sign In for Pricing
View Details PKSQ050017-02 50 µg
Recombinant Cynomolgus B7-2/CD86 Protein (Fc Tag)
Sign In for Pricing
View Details 